Early Friday morning, news broke that Japan’s Prime Minister Yoshihide Suga is ready to sign an agreement with Pfizer over the supply of the coronavirus (COVID-19) vaccines.
In doing so, the Asian major tries to tame the covid resurgence in areas surrounding Tokyo that signals the return of the virus-led activity restrictions.
Nikkei 225 remains mildly bid”¦
Nikkei 225 pays a little heed to otherwise trade-positive news. However, the risk barometer from Japan keeps 0.10% intraday gains by the press time. The reason for the equity gauge’s dismal reaction to the news could be traced from chatters over the Johnson & Johnson covid vaccine as well as geopolitical risks concerning China and Russia.
Read: S&P 500 Futures step back from record top as US Treasury yields pare weekly loss
Share
